Avalon Trust Co Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Avalon Trust Co raised its position in Eli Lilly and Company (NYSE:LLY) by 36.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 995 shares of the company’s stock after purchasing an additional 267 shares during the period. Avalon Trust Co’s holdings in Eli Lilly and Company were worth $580,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Forte Capital LLC ADV raised its holdings in Eli Lilly and Company by 7.0% in the 4th quarter. Forte Capital LLC ADV now owns 1,640 shares of the company’s stock valued at $956,000 after acquiring an additional 108 shares during the last quarter. Resolute Wealth Strategies LLC increased its holdings in shares of Eli Lilly and Company by 6.9% in the fourth quarter. Resolute Wealth Strategies LLC now owns 724 shares of the company’s stock valued at $422,000 after purchasing an additional 47 shares during the last quarter. Todd Asset Management LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth approximately $216,000. Royal Fund Management LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth $214,000. Finally, AJOVista LLC purchased a new stake in Eli Lilly and Company in the 4th quarter valued at $297,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.8 %

NYSE:LLY traded down $20.94 during trading hours on Friday, hitting $734.97. The company’s stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90. The stock has a market capitalization of $698.52 billion, a P/E ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. The stock has a fifty day moving average of $761.06 and a 200-day moving average of $671.38.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.62 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Truist Financial lifted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday. Bank of America increased their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Finally, Citigroup lifted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.